<DOC>
	<DOCNO>NCT00537121</DOCNO>
	<brief_summary>RATIONALE : Vorinostat may stop growth tumor cell block enzymes need cell growth . Drugs use chemotherapy , irinotecan , fluorouracil , leucovorin , work different way stop growth tumor cell , either kill cell stop divide . Giving vorinostat together combination chemotherapy may kill tumor cell . PURPOSE : This phase I trial study side effect best dose vorinostat give together irinotecan , fluorouracil , leucovorin treat patient advanced upper gastrointestinal cancer .</brief_summary>
	<brief_title>Vorinostat , Irinotecan , Fluorouracil , Leucovorin Treating Patients With Advanced Upper Gastrointestinal Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine maximum tolerate dose ( MTD ) recommend phase II dose ( RPTD ) vorinostat ( SAHA ) administer continuously standard dos irinotecan hydrochloride , fluorouracil , leucovorin calcium ( FOLFIRI ) patient advanced upper gastrointestinal cancer . - Determine MTD RPTD SAHA administer intermittently standard dos FOLFIRI patient . Secondary - Describe toxicity SAHA FOLFIRI combination . - Explore effect SAHA FOLFIRI combination TGF-β expression . - Explore alteration survivin expression SAHA FOLFIRI combination . - Describe effect FOLFIRI pharmacokinetics SAHA . - Describe effect SAHA pharmacokinetics irinotecan . - Describe response rate , progression-free survival , overall survival patient treat regimen . OUTLINE : Patients receive irinotecan hydrochloride IV 90 minute leucovorin calcium IV 2 hour day 1 fluorouracil IV continuously 46 hour day 1 2 ( FOLFIRI ) . Patients also receive oral vorinostat ( SAHA ) accord 1 follow dose regimen outline , depend upon time study entry : - Determination maximum tolerate dose ( MTD ) continuous SAHA dosing : Patients receive SAHA daily day 2-14 course 1 day 1-14 subsequent course . - Evaluation SAHA pharmacokinetics MTD continuous dose SAHA : Patients receive SAHA day -7 ( begin course 1 ) daily day 1-14 MTD . - Determination MTD intermittent SAHA : Patients receive SAHA daily day 1-7 MTD determine continuous SAHA dosing . Patients receive escalate dos SAHA MTD intermittent SAHA determine . Treatment FOLFIRI vorinostat repeat every 2 week 24 course absence disease progression unacceptable toxicity . Some patient undergo tumor tissue blood sample collection periodically pharmacokinetic correlative study . Tumor tissue sample assess TGF-β expression immunohistochemical method reverse transcriptase-polymerase chain reaction mRNA expression . Immunohistochemistry immunoenzymatic technique perform study survivin expression begin treatment completion course 1 . Pharmacokinetic study irinotecan , SN38 , SN38G obtain day 1 ( SAHA ) 15 ( SAHA ) . Blood also collect analysis UGT1A1 polymorphism . Other patient undergo blood collection day -7 ( FOLFIRI ) 2 ( FOLFIRI ) vorinostat Pharmacokinetic study . Samples analyze liquid chromatography-mass spectrometry . After completion study treatment , patient follow 4 week .</detailed_description>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Gastrointestinal Neoplasms</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Vorinostat</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm upper gastrointestinal tract cancer , include follow : Esophageal cancer ( adenocarcinoma squamous cell carcinoma ) Gastric cancer ( adenocarcinoma squamous cell carcinoma ) Hepatocellular carcinoma Locally advance , inoperable disease metastatic disease No uncontrolled brain metastasis PATIENT CHARACTERISTICS : ECOG performance status ( PS ) 01 ( Karnofsky PS ≥ 70 % ) Life expectancy &gt; 12 week Platelet count ≥ 100,000/mcL Absolute neutrophil count ≥ 1,500/mcL Leukocytes ≥ 3,000/mcL Total bilirubin ≤ 1.5 mg/dL AST ALT ≤ 2.5 time upper limit normal Creatinine ≤ 1.5 mg/dL OR creatinine clearance ≥ 60 mL/min Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception Able understand willing sign write informed consent document No history allergic reaction attribute compound similar chemical biologic composition vorinostat ( SAHA ) agent use study No uncontrolled intercurrent illness include , limited , follow : Ongoing active infection Symptomatic congestive heart failure Uncontrolled hypertension Unstable angina pectoris Cardiac arrhythmia Psychiatric illness/social situation would limit compliance study requirement No coagulopathy bleed disorder No known UGT1A1 polymorphism PRIOR CONCURRENT THERAPY : No 1 prior chemotherapy metastatic disease No prior histone deacetylase inhibitor No concurrent prophylactic hematologic growth factor No concurrent combination antiretroviral therapy HIVpositive patient No concurrent valproic acid No concurrent investigational therapy Concurrent therapeutic anticoagulation therapy allow</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>recurrent gastric cancer</keyword>
	<keyword>stage IV gastric cancer</keyword>
	<keyword>recurrent esophageal cancer</keyword>
	<keyword>stage IV esophageal cancer</keyword>
	<keyword>adenocarcinoma esophagus</keyword>
	<keyword>adenocarcinoma stomach</keyword>
	<keyword>squamous cell carcinoma esophagus</keyword>
	<keyword>adult primary hepatocellular carcinoma</keyword>
	<keyword>stage III gastric cancer</keyword>
	<keyword>stage III esophageal cancer</keyword>
	<keyword>advanced adult primary liver cancer</keyword>
	<keyword>localize unresectable adult primary liver cancer</keyword>
	<keyword>recurrent adult primary liver cancer</keyword>
</DOC>